Beijing: A Chinese pharmaceutical company has claimed that an experimental coronavirus vaccine developed by it has shown positive results in human trials.
The early results from tests suggested that the experimental vaccine could be safe and effective against the SARS-CoV-2 virus, the Beijing-based China National Biotec Group (CNBG) said on Sunday.
In a posting on social media platform WeChat, CNBG said that preliminary data of the trial involving 1,120 healthy people showed that the experimental vaccine induced high-level antibodies in all the participants in a Phase 1/2 clinical study, Times Now reported.
According to CNBG, which is affiliated to the state-owned China National Pharmaceutical Group (Sinopharm), this was the second vaccine candidate from the firm to produce promising results in a clinical trial.
Chinese researchers and firms have been allowed to test eight vaccine candidates in humans at home and abroad.
Reports suggest that China, which is among front-runners in the race to find a COVID-19 jab, is developing coronavirus vaccines in five categories — inactivated vaccines, recombinant protein vaccines, live attenuated influenza vaccines, adenovirus vaccines and nucleic acid-based vaccines.
Also Read: Countering COVID: Oxford Vaccine At Most Advanced Stage & Are Frontrunners: WHO
Comments are closed.